STOCK TITAN

Black Diamond Therapeutics to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Black Diamond Therapeutics, a leader in precision oncology, announced its CEO, David M. Epstein, will present a corporate update at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 28, 2021, at 4:40 PM ET. This presentation is significant for shareholders and interested parties as it highlights the company's advancements in developing MasterKey therapies targeting undrugged mutations in genetically defined cancers. A live webcast will be available on their website with a replay accessible for three weeks.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass. and NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 4:40 PM ET.

A live webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the presentation will also be available and archived on the site for three weeks.

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform and drug discovery engine, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy that targets a specific family of mutations, termed a MasterKey therapy. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts
For Investors:
Natalie Wildenradt
investors@bdtx.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com


FAQ

When is Black Diamond Therapeutics' presentation at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference?

Black Diamond Therapeutics' presentation is scheduled for September 28, 2021, at 4:40 PM ET.

Who is presenting for Black Diamond Therapeutics at the conference?

David M. Epstein, the President and CEO of Black Diamond Therapeutics, will present at the conference.

How can I access the webcast of the Black Diamond Therapeutics presentation?

You can access the live webcast of the presentation on Black Diamond Therapeutics' investor relations website.

What are MasterKey therapies developed by Black Diamond Therapeutics?

MasterKey therapies target undrugged mutations in patients with genetically defined cancers, utilizing their proprietary MAP platform.

How long will the replay of the presentation be available?

The replay of the presentation will be available and archived on the website for three weeks.

Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

BDTX Rankings

BDTX Latest News

BDTX Stock Data

125.34M
55.24M
2.26%
98.75%
10.49%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE